Security Check
Dr. Peng Liu

Dr. Peng Liu, MD, Ph.D.

Senior Consultant
Code: 110440000025922
Hem-Onc (Hematological Oncology) MO (Medical Oncology) ML (Malignant Lymphoma) CIT (Cellular Immunotherapy) NTT (Novel Targeted Therapy)
Experience20+ years
LanguagesEnglish | 中文
Typical turnaround3–5 business days
Second-opinion formatWritten review

Overview

Dr. Peng Liu is a Chief Physician, Professor, and PhD Supervisor. He currently serves as the Deputy Director of the Department of Lymphoma at Sun Yat-sen University Cancer Center (SYSUCC). A standing committee member of the CSCO Anti-Lymphoma Alliance, he is a renowned national expert in hematological oncology, highly esteemed for the precision diagnosis, whole-course management, and individualized treatment of malignant lymphoma.

Board Certification
Breast Surgery
Clinical Focus
ML-Precision (Malignant Lymphoma Precision Therapy) | ITT (Immune Checkpoint Inhibitor Therapy) | CAR-T (Cellular Immunotherapy) | MS-Prognosis (Molecular Subtyping & Prognostic Assessment) | CCT (Combination Chemotherapy & Targeted Therapy)
Approach
Guideline-driven + personalized
Best for
New diagnosis · Recurrence · Complex decisions
Clinical focus & conditions

1.Aggressive Lymphomas
Precision management of DLBCL, Mantle Cell Lymphoma (MCL), and NK/T-cell Lymphoma.
Comprehensive treatment for Hodgkin Lymphoma (HL).
2.Indolent Lymphomas
Long-term clinical care for Follicular Lymphoma and Marginal Zone Lymphoma (MZL).
3.Plasma Cell Dyscrasias
Multi-line integrated therapy and whole-course management of Multiple Myeloma (MM).

Education & training

MD,Ph.D. — Sun Yat-sen University of Medical Sciences
Training — National Cancer Institute (NCI), NIH (USA)

Hospital affiliations

Sun Yat-sen University Cancer Center

Honors & Research

Honors:
Recipient of the First Prize of Guangdong Science and Technology Progress Award, First Prize of Guangzhou Science and Technology Progress Award, and the CSCO Young and Middle-aged Oncologist Award.
Academic Affiliations:
Standing Committee Member of the CSCO Anti-Lymphoma Alliance; Standing Committee Member of the Lymphoma Committee of CACA; Vice Chairman of the Lymphoma Committee of the Guangdong Anti-Cancer Association.
Research:
PI for numerous National Natural Science Foundation and provincial major research projects. Published over 40 SCI papers in prestigious journals such as Blood, JCO, and Nature Communications.

Is my case a fit for a second opinion?

A second opinion is often helpful if you have a new diagnosis multiple treatment options discordant pathology or imaging results  progression/recurrence or you want confirmation before starting therapy.
•Good fit: complex decisions uncertainty multiple lines of therapy clinical trial questions.
•Not a fit: emergencies (e.g. severe symptoms acute complications). Seek urgent local care.

Important note

This page is for educational and second-opinion purposes. It is not a substitute for emergency care or an in-person exam. If you have urgent symptoms, contact local emergency services.